01050nas a2200145   4500008004100000024000700041245003100048210003000079260001800109300001000127490000600137520068300143100001800826856006000844       2023                        eng d  a0300aDrug Review: Eflapegrastim0 aDrug Review Eflapegrastim  cNovember 2023  a52-530 v93 a<p class="rtejustify">Registrations: It had been registered in the following countries United States of America (USA), United Kingdom (U.K.), Canada, and Saudi Arabia (S.A.) Trade name (USA); ROLVEDON Registration number (S.A.); Not Available. Insurance Drug Formulary (S.A.); Not covered (29.1.2023). General Information: Registered Company: Spectrum Pharmaceuticals. Regulatory Status: R.X. Mechanism of Action: A recombinant human granulocyte growth factor activates signaling pathways that affect cell differentiation, proliferation, migration, and survival by binding to G-CSF receptors on myeloid progenitor cells and neutrophils.&nbsp;<strong> Read more...</strong></p>
1 aAlsaab, Juman  uhttps://ptbreports.org/article/2023/9/2/105530ptb202398